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Abstract
Introduction: Recent studies have shown an increased risk of lung cancer in patients with bronchial ob-
structive changes, including patients with COPD. It seems that there are common factors of pathogene-
sis of both diseases associated with oxidative stress. In the present paper the genes linked to the repair of oxida-
tive damage of DNA, associated with cancer, of iron metabolism and coding proteolytic enzymes were assessed. 
Material and methods: The study was conducted in two groups of patients: 53 patients with non-small 
cell lung cancer and chronic obstructive pulmonary disease, and 54 patients only with chronic obstructi-
ve pulmonary disease. The polymorphisms of the single nucleotide were determined in the case of the majori-
ty of genes using the PCR-RFLP method. The statistical analysis of quantitative variables was executed using the Mann - 
-Withney U-test and the test of medians; the analysis of genetic variables was executed using the c² test. 
Results: Regarding the polymorphisms of genes involved in iron metabolism, statistically significant differen-
ces between the two groups have been demonstrated only in the case of haptoglobin gene HP1/2. A higher inciden-
ce of form 1/1 was found in patients with COPD and a higher incidence of form 1/2 in patients with lung cancer 
and COPD. Analysis of gene polymorphisms of proteolytic enzymes and inhibitors of the enzyme gene showed sta-
tistically significant differences between the two groups only for the MMP3 gene 6A/5A. In the case of the MMP12 
gene polymorphism (A-82G) a tendency toward differences in the occurrence of specific alleles was identified. 
Conclusions: These results indicate that patients with coincidence of COPD and lung cancer have disorders of the genes involved 
in iron metabolism, and they have different genetic polymorphisms of proteolytic enzymes comparing to COPD patients.
Key words: lung cancer, chronic obstructive pulmonary disease (COPD), oxidative stress, genetic polymorphism, haptoglobin, 
metalloproteinases
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Streszczenie
Wstęp: Dotychczasowe wyniki badań wskazują na zwiększone ryzyko zachorowania na raka płuca u osób ze zmianami 
obturacyjnymi oskrzeli, w tym u chorych na przewlekłą obturacyjną chorobę płuc (POChP). Wydaje się, że istnieją wspólne 
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Introduction
The increased risk of lung cancer in patients 
with chronic obstructive pulmonary disease is 
more and more frequently becoming the subject 
of recent research projects. The results of research 
published in 1977 by Cohen et al. suggested an 
increased risk of the occurrence of respiratory tract 
obstruction in first line relatives of lung cancer 
patients and in relatives with COPD, regardless of 
tobacco smoking or other risk factors [1]. In 1986 
a prospective research project was published. 
It consisted of monitoring for 10 years, from the 
point of view of lung cancer incidence, two groups 
of people who smoked cigarettes: patients with 
COPD (FEV1 < 70%) and a control group with FEV1 
> 85% of the predicted value. The incidence of 
lung cancer among patients with COPD was 8.8% 
and among the control group it was 2% [2]. The 
research carried out by Tockman et al. in 1987 
showed an increased risk of lung cancer occur-
rence along with deterioration of lung function 
and a drop in FEV1 [3]. More frequent lung cancer 
occurrence in patients with low values of FEV1 
and the increase of risk dependent on lowering 
of this parameter has also been shown in a study 
from 1994 that assessed the American population 
[4]. Similar conclusions have been drawn by other 
researchers [5, 7], who, additionally, showed an 
increased risk of mortality from lung cancer de-
pendent on FEV1 impairment degree. In The First 
National Health and Nutrition Examination Survey 
(follow-up research conducted on a group of 5402 
people) it was established that former smokers with 
moderate COPD had a higher risk of lung cancer 
czynniki patogenetyczne obu chorób związanych ze zjawiskiem stresu oksydacyjnego. Przedmiotem oceny stały się geny 
związane z procesami naprawy oksydacyjnych uszkodzeń DNA, geny związane z nowotworami, z metabolizmem żelaza 
i geny enzymów proteolitycznych. 
Materiał i metody: Badanie przeprowadzono w dwóch grupach pacjentów liczących łącznie 107 osób: 53 chorych na raka 
niedrobnokomórkowego płuca i POChP oraz 54 chorych tylko na POChP. W przypadku większości genów oznaczono polimor-
fizm pojedynczego nukleotydu metodą analizy długości fragmentów restrykcyjnych (RFLP). Analizy statystycznej zmiennych 
ilościowych dokonano testem U Manna-Whitneya i testem median, analiza zmiennych genetycznych została dokonana 
testem Chi-kwadrat.
Wyniki: W przypadku polimorfizmu genów związanych z metabolizmem żelaza istotne statystycznie różnice pomiędzy ba-
danymi grupami wykazano jedynie w przypadku genu haptoglobiny Hp1/2. Stwierdzono częstsze występowanie formy 1/1 
w grupie chorych na POChP i częstsze występowanie formy 1/2 w grupie chorych na raka płuca i POChP. Analiza polimorfizmu 
genów enzymów proteolitycznych i genu inhibitora tych enzymów wykazała istotne statystycznie różnice pomiędzy badany-
mi grupami jedynie w przypadku genu metaloproteinazy MMP3 6A/5A. W przypadku polimorfizmu genu metaloproteinazy 
MMP12 (A-82G) różnice w występowaniu poszczególnych alleli określono na poziomie tendencji. 
Wnioski: Wyniki te wskazują, że u chorych z koincydencją POChP i raka płuca występowały różnice w stosunku do grupy 
chorych na POChP dotyczące genów związanych z metabolizmem żelaza oraz genów enzymów proteolitycznych.
Słowa kluczowe: rak płuca, przewlekła obturacyjna choroba płuc (POChP), stres oksydacyjny, polimorfizm genetyczny, 
haptoglobina, metaloproteinazy
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incidence (6.7%) in comparison with the whole 
group of former smokers in whom the risk was two 
times lower [6].
The above-mentioned data allow the conclu-
sion to be drawn that COPD may be an independ-
ent factor that contributes to the development of 
lung cancer, and the frequency of the occurrence 
of this neoplasm probably depends on COPD 
progression. It has been revealed that diagnosis of 
COPD increases the risk of lung cancer incidence 
irrespective of tobacco smoking [8], and it has been 
suggested that it does not depend on age or sex, 
while in former smokers the probable pathogenic 
mechanism for both diseases is a chronic inflam-
matory process of the respiratory tract [9].
Among the pathogenic processes that are 
responsible for development of changes in res-
piratory tract in the course of COPD, neutrophilic 
inflammation, disorders of proteases/antipro-
teases system equilibrium, and oxidative stress 
caused by overproduction of oxygen free radicals 
and depletion of antioxidative reserves should be 
listed [10]. During the course of oxidative stress, 
DNA may be damaged due to nitrogenous base 
oxidation, DNA strand rupture and chromosomes 
injuries — it may consequently lead to disorders 
during the process of genetic material replica-
tion, which in turn may cause the death of cells 
or neoplastic mutation. The process of creation 
of oxygen radicals happens frequently in the 
presence of iron ions Fe2+; therefore, disorders of 
homeostasis of this microelement may be of vital 
significance. It is supposed that in the cells that 
undergo oxidative stress, intercellular changes 
in iron and copper homeostasis occur.
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The repair of damaged DNA, among others, 
with the help of BER enzymes, which remove the 
damaged base, or with the help of NER enzymes, 
which remove damaged DNA fragment, is an or-
ganism’s natural defence mechanism against the 
effects of oxidative stress. Another known means 
of DNA repair is DSBR, which is connected with 
the repair of double-strand breaks [11, 12]. A key 
role in the repair of damaged DNA caused by oxi-
dative stress in people exposed to tobacco smoke 
is attributed to the BER system [13]. Polymorphism 
of the genes that code these enzymes and their 
reduced activity may influence the development 
of neoplastic processes [14].
Transcription and growth factors such as 
proteins p53, p21 and TNF-α play a crucial role 
in carcinogenesis; the appearance of mutation or 
disturbances of gene expression of these factors 
influence the development of both lung cancer 
and COPD. Genes coding proteolytic enzymes of 
metalloproteinase (MMP) and the MMP inhibitors 
(TIMP) may be involved in COPD. MMP not only 
influences the alteration of stromal connective 
tissue in the course of inflammatory processes and 
necrosis, but also facilitate angiogenesis and the 
growth of neoplastic tumours. The MMP-1 overex-
pression is associated with tumour invasion and 
metastasis formation [16]; in research conducted 
by Sue et al. it was suggested that polymorphism 
of the MMP-1 gene, of certain MMP-3 and MMP-12 
genes, haplotypes play a role in increased risk of 
lung cancer occurrence [17, 18].
The purpose of this study was to assess the 
influence of genetic factors on lung cancer and 
COPD occurrence. Polymorphism of genes con-
nected with the repair processes of DNA oxidative 
damage and polymorphism of genes connected 
with neoplasms, iron and proteolytic enzymes 
metabolism have been assessed; subsequently 
the genetic variation in the group of patients with 
COPD and the group with COPD and non-small 
cell lung cancer were assessed. 
Material and methods
The research was conducted on two groups of 
patients randomized in respect of sex, age, tobacco 
addiction and recognition of the disease. The pa-
tients were diagnosed and treated in the Institute 
of Tuberculosis and Lung Diseases in Warsaw in 
the years 2007-2009. The first group (Group I) con-
sisted of patients with COPD and non-small cell 
lung cancer, whereas the second group (Group II) 
consisted of patients only with COPD. Only men 
at the age of the highest incidence of lung cancer 
and COPD, i.e. age 50–70-year-old, participated 
in the research. Tobacco addiction was measured 
in pack-years.
COPD diagnosis was established on the gro-
unds of medical history, symptoms of disease and 
additional examinations including spirometric te-
sting in accordance with established international 
criteria GOLD. Lung cancer diagnosis was made on 
the grounds of histopathological examination of: 
a) tumour specimens taken during bronchoscopy, 
b) punctate taken from mediastinal lymph nodes 
during EBUS, c) punctate taken from tumours 
during needle biopsy through the chest wall, d) 
mediastinoscopy and e) postoperative examination 
of removed tumours. The research was conducted 
in the Pathomorphology Department of the Institu-
te of Tuberculosis and Lung Diseases.
Clinical assessment of respiratory tracts
All patients underwent spirometry with 
diastolic test, pulmonary function tests with 
DLCO, walk test, gasometry at rest, chest X-ray 
and computer tomography of the chest. Spi-
rometric testing was conducted in the Lung 
Function Department of the Institute of Tuber-
culosis and Lung Diseases using MedGraphics 
apparatus. The research procedure was held in 
accordance with ERS/ATS international standards. 
Reversibility test was made after inhalation of sal-
butamol, administered in four separate doses of 
100 micrograms, which were given at 30 seconds 
intervals. The increase in FEV1 or FVC exceeding 
200 ml and 12% of predicted value for these para-
meters was recognized as a positive result of the 
test. Body plethysmography was made using Master 
Screen Body apparatus. RV/TLC > ULN (upper limit 
of normal) was recognized as pulmonary hyperinfla-
tion, whereas VA/TLC < 0.85 was recognized as an 
index of disturbance of gas distribution. Assessment 
of DLCO impairment was based on the percentage 
predicted value of this parameter.
Gasometry was carried out in the Department 
of Laboratory Diagnosis in the Institute of Tuber-
culosis and Lung Diseases with the help of a pH 
and blood gases analyser 248 from Ciba Corning 
Diagnostic. Walk test was conducted in the Second 
Department of Lung Diseases in the Institute of 
Tuberculosis and Lung Diseases in accordance with 
ATS standards; it consisted of covering the longest 
possible distance during a six-minute walk in an 
indicated part of the hospital corridor. O2 satura-
tion was measured with the help of percutaneous 
method and pulse oximeter before testing, in the 
course thereof and after it; the covered distance 
was estimated. 
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Imaging studies included: chest radiological 
examination (RTG) and computer tomography 
(CT). All examinations were carried out in the Ra-
diology Department of the Institute of Tuberculosis 
and Lung Diseases. Computer tomography of the 
chest was performed using CT Somaton Sensation 
16 apparatus from Siemens, with the use of the 
spiral technique with intravenous administration 
of non-ionic contrast medium.
Evaluation of genetic polymorphism
Examination of gene polymorphism was exe-
cuted in the Department of Radiobiology and 
Health Care in the Institute of Nuclear Chemistry 
and Technology in Warsaw. Single nucleotide poly-
morphisms (SNP) were determined in the majority 
of genes. The method of analysis of restriction 
fragment lengths, which uses restriction fragment 
length polymorphism (RFLP), was applied. This 
method consists of digesting amplified DNA frag-
ments using the PCR technique, which includes 
the place of occurrence of polymorphism, with 
a suitable restrictive enzyme. The tested SNP 
occurs in a sequence that is recognized by the 
enzyme which cuts the DNA molecule only in the 
presence of one allele. Multiplex PCR technique, 
which uses another gene for positive checking, was 
used for polymorphism examination consisting of 
gene deletion. Gene promoter polymorphisms that 
consisted of d(CA) or d(GG) sequence duplication 
were tested using the PCR method (Tab. 1).
Statistical analysis
Statistical analysis of quantitative variables 
was carried out using the Mann-Withney U test 
(nonparametric test) and the test of medians. The 
value of p < 0.05 was taken as the significance 
level. Additionally, in order to evaluate the dif-
ference between distributions in the groups, the 
Kolmogorov-Smirnov test was used. Statistical 
evaluation of genetic variables was done with the 
use of the χ² test; the results include numerical 
and percentage values.
Results
Group I consisted of 53 patients. The avera-
ge pack-years in this group was 49.72. Group II 
consisted of 54 patients. The average pack-years 
in this group was 42.28. The difference in to-
bacco exposure was not statistically significant. 
Spirometric examination showed more advanced 
changes in lung function in the course of COPD 
in Group II — the assessment of forced expira-
tory volume in 1 second in patients from Group 
II revealed significantly decreased parameters 
in comparison with Group I. Group II also had 
a lower average value of forced vital capacity FVC 
(Tab. 2). Squamous carcinoma was diagnosed 
in 10 patients from group I, adenocarcinoma in 
6 patients, and large cell carcinoma in 3 patients. 
Non-small cell cancer without precise definition 
of histopathological type was diagnosed in the 
remaining 34 patients. 
Greater hypoxemia (average values pO2 60.94 
mm Hg vs. 69.47 mm Hg) and hypercapnia (ave-
rage values pCO2 44.48 mm Hg vs. 37.52 mm Hg) 
were noted in Group II. More serious disorders 
of gas exchange were correlated with the highest 
COPD stage. The degree of pulmonary hyperinfla-
tion was highest in patients from Group II (Tab. 3).
Lung imaging in the group with cancer and 
COPD showed the presence of radiological features 
of COPD in 25 patients (47.17%), whereas in the 
group with COPD only, such features were noted 
in 45 patients (83.33%).
DNA repair genes, which remove the damage 
caused by genetic mutations, were assessed first. 
Single nucleotide polymorphisms (SNP) were 
determined in the majority of repair genes. Poly-
morphism of the following genes was determined: 
XRCC1 Arg194Trp, XRCC1 Arg399Gln, hOGG1 
Ser326Cys, MYH Y165C, MYH G382D, XPA 5’UTR 
A(-4)G, XPD Lys751GlnA/C, XRCC3 Thr241Met 
C/T, XRCC4 Ile401Thr. No significant differences 
in the polymorphism of these genes between the 
groups were noted. 
The next group of evaluated genes were prote-
in genes connected with neoplasms. Polymorphism 
of the following genes were determined: TP53 
Arg72Pro, CDKN1A Ser31Arg, CDKN1A Ln2 C/G, 
CDKN1A UTR C/T, TNF-α, G-308A. No significant 
differences in the polymorphism of these genes 
between the evaluated groups was noted.
Genes connected with iron metabolism, i.e. 
haptoglobin, hepcidin and ferroportin, were also 
included in the research (Tab. 4); disturbances of 
iron homeostasis, which catalyses reactions of 
creation of some oxygen radicals, may be of some 
significance from the point of view of oxidative 
stress. The presence of alleles of the haptoglobin 
gene was determined using the PCR method; the 
difference between the alleles Hp1 and Hp2 con-
cerned the presence of a duplicated DNA segment 
with a length of 1,700 base pairs in the Hp2 allele.
The research results showed that in the case 
of the haptoglobin gene HP1/2 the occurrence of 
the 1/1 allele was more common in the group of pa-
tients with COPD, whereas the 1/2 allele was more 
frequently found in patients with lung cancer and 
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Table 1. Polymorphisms of genes
Gene Gene’s ID Determined polymorphism
MMP1 
Matrix metallopeptidase 1 (interstitial collagenase)
4312 -1607 1G/2G
MMP3 
Matrix metallopeptidase 3 (stromelysin 1, progelatinase)
4314 -1171 5A/6A
MMP9 
Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)
4318 C-1562T
MMP12
Matrix metallopeptidase 12 (macrophage elastase)
4321 Asn357Ser
A-82G
TIMP2
TIMP metallopeptidase inhibitor 2
7077 G-418C
TNF-a
Tumour necrosis factor (TNF superfamily, member 2)
7124 G-308A
SLC40A1 (alias: ferroportin)
Solute carrier family 40 (iron-regulated transporter), member 1
30061 Q248H
XPA
Xeroderma pigmentosum, complementation group A
7507 5’ UTR A-4G
XPD (ERCC2) 
Excision repair cross-complementing rodent repair deficiency, 
Complementation group 2
2068 Lys751Gln
XRCC3
X-ray repair complementing defective repair in Chinese hamster cells 3
7517 Thr241Met
TP53
Tumour protein p53
7157 Arg72Pro
CDKN1A
Cyclin-dependent kinase inhibitor 1A (p21, Cip1)
1026 Ser31Arg
C/G intron 2 rs3176352
C/T 3’UTR rs1059234
MUTYH
mutY homolog (E. coli)
4595  Tyr165Cys
Gly382Asp
XRCC1
X-ray repair complementing defective repair in Chinese hamster cells 1
7515 Arg194Trp
Arg399Gln
OGG1
8-oxoguanine DNA glycosylase
4968 Ser326Cys
XRCC4
X-ray repair complementing defective repair in Chinese hamster cells 4
7518 Ile401Thr 
HAMP
Hepcidin antimicrobial peptide
57817 Gly71Asp
HP
Haptoglobin
3240 Hp1/Hp2
COPD. The 2/2 allele was slightly more common in 
patients with COPD; these differences were signifi-
cant. The determined polymorphisms of the hepcidin 
gene HAMP (Gly71Asp) and ferroportin SLC40A1 
(Q248H) demonstrated the occurrence of only one 
kind of genotype in all the investigated patients. 
The last examined group of genes were genes 
of proteolytic enzymes MMP (metalloproteinases) 
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Table 2. Patients’ characteristics with spirometry
Medical factors Group I (lung cancer + COPD)
n = 53
Group II (COPD)
n = 54
p
Age (years) 60.60 ± 6.16 61.93 ± 5.74 NS
Height [cm] 173.08 ± 5.70 169.93 ± 7.60 NS
Weight [kg] 75.31 ± 15.35 82.43 ± 22.03 NS
BMI [kg/m²] 25.10 ± 4.70 28.64 ± 7.87 p < 0.05
FEV1 [L]
FEV1%
1.95 ± 0.75
61.19 ± 21.98
1.10 ± 0.51
35.98 ± 16.34
p < 0.001
p < 0.001
FVC [L]
FVC%
3.49 ± 0.98
86.32 ± 23.77
2.58 ± 0.79
65.04 ± 20.4
p < 0.001
p < 0.001
FEV1/FVC (%) 55.26 ± 10.79 43.32 ± 11.35 p < 0.001
Table 3. Gasometry at rest, gasometry after exertion and plethysmography
Medical factors Group I (lung cancer + COPD) Group II (COPD) p
pH 7.43 ± 0.02 7.41 ± 0.03 p < 0.001
pO2 [mm Hg] 69.47 ± 8.44 60.94 ± 8.93 p < 0.001
pCO2 [mm Hg] 37.52 ± 4.23 44.48 ± 8.98 p < 0.001
HCO3 24.67 ± 2.25 27.62 ± 3.66 p < 0.001
satO2 (%) 94.08 ± 1.86 90.79 ± 3.88 p < 0.001
spO2 max (%) 95.77 ± 2.13 92.16 ± 4.60 p < 0.001
spO2 min (%) 90.0 ± 6.62 83.92 ± 6.68 p < 0.001
TLC [L] 7.57 ± 1.53 8.47 ± 1.48 p < 0.05
TLC (%) 113.22 ± 21.79 130.90 ± 22.26 p < 0.001
RV [L] 3.84 ± 1.27 5.34 ± 1.48 p < 0.001
RV (%) 163.10 ± 52.78 226.78 ± 61.07 p < 0.001
Raw [L] 0.34 ± 0.18 0.62 ± 0.29 p < 0.001
Raw (%) 113.57 ± 58.73 206.54 ± 100.15 p < 0.001
DLCO [L] 5.70 ± 1.91 4.23 ± 2.09 p < 0.01
DLCO (%) 62.17 ± 19.87 47.59 ± 22.17 p < 0.01
and the enzyme inhibitor thereof, TIMP2. In the 
group of metalloproteinases the polymorphisms 
of the 1st, 3rd, 9th and 12th metalloproteinase were 
determined (Tab. 5).
Significant differences were observed concer-
ning the polymorphism of the MMP3 gene (6A/5A). The 
5A/5A homozygote was present twice as frequently in 
patients from Group I as in group II. In this group the 
occurrence of the 6A/6A homozygote was also observed 
twice as frequently comparing with Group II (18 vs 
9), while the 6A/5A genotype was present in Group 
II almost twice as frequently comparing with Group 
I. Analysis of the MMP3 gene polymorphism proved 
a statistical significance. Analysis of research results 
also revealed certain differences in the polymorphism 
of the MMP12 gene. In the case of MMP12 polymor-
phism (A-82G), a frequent occurrence of the A/G allele 
was shown in patients with lung cancer and COPD. The 
Pneumonologia i Alergologia Polska 2013, tom 81, nr 4, strony 308–318 
314 www.pneumonologia.viamedica.pl
Table 4. Polymorphism of genes connected with iron metabolism
Gene SNP Genotype Group I
n (%)
Group II
n (%)
All patients p
HP Hp 1/2 1/1
1/2
2/2
5 (31.3)
27 (64.3)
21 (42.9)
11 (68.8)
15 (35.7)
28 (57.1)
16
42
49
0.03563
HAMP Gly71Asp Gly/Gly 53 (49.5) 54 (50.5) 107
SLC40A1
(ferroportin)
Q248H Gln/Gln 53 (49.5) 54 (50.5) 107
 
Table 5. Polymorphism of genes of proteolytic enzymes and of their inhibitor
Gene SNP Genotype Group I
n (%)
Group II
n (%)
All patients P
MMP1 1607 1G/2G 1G/1G
1G/2G
2G/2G
12 (41.4)
26 (55.3)
15 (48.4)
17 (58.6)
21 (44.7)
16 (51.6)
29
47
31
NS
MMP3 6A/5A 5A/5A
6A/5A
6A/6A
16 (64.0)
19 (34.5)
18 (66.7)
9 (36.0)
36 (65.5)
9 (33.3)
25
55
27
0.00608
MMP9 C-1562T C/C
C/T
T/T
42 (51.2)
11 (45.8)
0 (0.0)
40 (48.8)
13 (54.2)
1 (100.0)
82
24
1
NS
MMP12 Asn357Ser Asn/Asn
Asn/Ser
51 (51.0)
2 (28.6)
49 (49.0)
5 (71.4)
100
7
NS
A-82G A/A
A/G
G/G
36 (43.9)
14 (63.6)
3 (100.0)
46 (56.1)
8 (36.4)
0 (0.0)
82
22
3
0.05376
TIMP2 G-418C G/G 53 (49.5) 54 (50.5) 107
A/A allele was more frequent in patients with COPD, 
whereas the G/G allele was present only in patients from 
Group I (cancer + COPD). These differences were not 
statistically significant. The determined polymorphism 
of the gene inhibitor of metalloproteinases TIMP2 (G/C) 
demonstrated the occurrence of only one G/G genotype 
in all the examined patients in both groups.
Discussion
In order to obtain maximum homogeneity 
of the investigated groups, patients qualified for 
the research were chosen in respect of sex, age, 
tobacco smoking addiction and diagnosis of a di-
sease. Occupational exposure to harmful agents or 
family history of hereditary disease were not taken 
into account during the research. The examined 
patients were diagnosed with COPD in different 
stages; patients with mild or moderate degree of 
disease predominated in Group I, whereas patients 
with serious or very serious COPD predominated 
in Group II. However, for the evaluation of coin-
cidence of genetic predisposition between lung 
cancer and chronic obstructive pulmonary disease 
(genotypic evaluation), such selection of patients 
seemed to be acceptable. 
The main purpose of this study was to de-
termine whether the polymorphism of genes that 
participate in the defence mechanism against 
oxidative stress influence the coincidence of 
lung cancer and chronic obstructive pulmonary 
disease. Genes connected with the repair of da-
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maged DNA were analysed first. In the scope of 
the BER system the polymorphism of three genes: 
XRCC1, hOGG1 and MYH was assessed, the re-
search did not reveal any statistically significant 
differences between the two compared groups. 
The multicentre research conducted by Matullo 
et al., published in 2006, suggested a protective 
effect of the Gln/Gln homozygote of the XRCC1 
Arg399Gln gene in lung cancer [12], and similar 
results were obtained by Spanish authors in 2007 
[19]. The present research did not prove such 
a dependence. Analysis of hOGG1 Ser326Cys gene 
polymorphism showed it to be the least frequent 
occurrence of the Cys/Cys homozygote in the two 
groups of patients; the research conducted among 
the Chinese population [15] showed an increasing 
risk of occurrence of COPD among patients with 
this genotype; such a dependence has also been 
suggested for the Gln/Gln genotype of the XRCC1 
Arg399Gln gene among active tobacco smokers 
and for the Arg/Gln genotype among heavy smo-
kers. Analysis of polymorphism of DNA repair 
genes of the NER system included two genes: XPA 
and XPD. The determined polymorphism of these 
genes did not show any statistically significant 
differences in the two examined groups of pa-
tients. Previous research projects have suggested 
a probable dependence of XPD Lys751Gln poly-
morphism on the risk of lung cancer occurrence 
in patients who smoke cigarettes (an increased 
risk of lung cancer occurrence in carriers of 
trait CC and CA vs. AA). Such a dependence 
was also observed in other research projects in 
former smokers who were carriers of the Gln/Gln 
homozygote and the Lys/Gln heterozygote [12, 21]. 
Analysis of DNA repair gene polymorphism con-
nected with the DSBR repair system did not show 
any statistically significant differences either. 
XRCC3 Thr241Met gene polymorphism has been 
mentioned hitherto as a polymorphism that night 
be connected with the occurrence of lung cancer 
in smokers [21]. The mentioned study suggested 
a possible interaction of this gene with the XRCC-
-1-Arg399Gln and XPD-Lys751Gln genes. 
The next group of analysed genes was connec-
ted with the process of neoplastic transformation. 
Evaluation has concerned genes coding the p21 
protein, the p53 protein and tumor necrosis factor 
TNF-a. CDKN1A gene coding of the p21 protein 
demonstrated polymorphism of three codons: 
Ser31Arg, In 2C/G and UTR C/T. None of the deter-
mined polymorphisms was distinguished by stati-
stical significance in the frequency of occurrence of 
individual genotypes. The p21 protein is a kinase 
inhibitor; it also influences division processes in 
cell growth cycle and participates in DNA repair 
regulation — disturbances of regulation of p21 
concentration may influence the process of neopla-
stic transformation [22]. Several published studies 
concerning polymorphism of the p21 Ser31Arg 
gene did not find any dependence between the 
occurrence of definite genotypes or any increased 
risk of lung cancer occurrence [23, 24]. Yao-Ling et 
al. in their research of 2006 concerning polymor-
phism of the p21 and p53 genes in patients with 
COPD (vs. healthy humans) showed an increased 
risk of the COPD occurrence in tobacco smokers 
and patients with the Arg/Arg and Ser/Arg genotype 
of the p21 Ser31Arg gene [25].
The majority of studied mutations of the TP53 
gene are point mutations that lead to a change in 
a single amino acid, or they are deletions of a gene 
fragment. The TP53 gene codes the p53 protein, 
which is called a guard of the genome due to its 
function of sensor of DNA damage. The research 
conducted by Yao-Ling et al. showed an increased 
risk of COPD occurrence in tobacco smokers with 
the Pro/Pro and Arg/Pro genotype of the TP53 
Arg72Pro gene [25]. Studies concerning TP53 gene 
polymorphism have not proven any dependence 
between genotypes and the risk of occurrence 
of lung cancer, whereas a tendency toward the 
occurrence of the Pro/Pro allele has been shown 
in patients with adenocarcinoma [26]. Studies 
conducted subsequently seem to confirm an incre-
ased risk of lung cancer occurrence for the Pro/Pro 
homozygote — contrary to the Arg/Arg homozygote 
[27, 28]. In this study, analysis of the TP53 gene 
polymorphism and the other gene, TNF-a, did 
not show any statistically significant differences 
between the two groups. The TNF-a gene under-
went evaluation of G-308 A polymorphism. The 
TNF-a is one of the main cytokines that participate 
in inflammatory and immune response, it shows 
antineoplastic properties and it may also influence 
the process of angiogenesis [29]. The role of TNF-a 
concerns, among others, the damage of epithelial 
cells caused by this pro-inflammatory cytokine in 
the presence of the stimulated T lymphocytes or 
by release of metalloproteinases from stimulated 
macrophages [30]. Research of TNF-a G-308A gene 
polymorphism in patients with COPD has shown 
that people with the A/A homozygote are predispo-
sed to greater changes in obstructive respiratory 
tract and have worse prognosis in the course of 
this disease [31]. TNF-a G-308A polymorphism has 
also been investigated in patients with non-small 
cell lung cancer, and a higher risk of occurrence 
of this neoplasm has been connected with the A/A 
and G/A genotype [32].
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A statistically significant difference was noted 
in genes connected with iron metabolism; the dif-
ference concerned the gene of the haptoglobin (HP) 
(HP). It was shown that the Hp1/1 form occurs more 
frequently in patients with COPD (twice as frequ-
ently as in the group of patients with lung cancer 
and COPD). While patients from Group I (cancer 
+ COPD) more frequently had the 1/2 genotype 
(almost twice as frequently). The 2/2 homozygote 
was discovered with similar frequency in the two 
groups of patients (slightly more often in the group 
with COPD only). In the whole examined popula-
tion of patients the genotypes 1/2 and 2/2 appeared 
most frequently; the 1/1 genotype appeared the 
most rarely, in accordance with the tendency that 
genotype 2/2 vs. 1/1 prevails in Europe [33]. Hapto-
globin is a protein of the acute phase, which binds 
free haemoglobin and prevents the kidneys from 
losing free haemoglobin together with iron ions, 
which are precious for the organism [34]. There 
are 3 phenotypic forms of this protein identified 
in humans: Hp1-1, Hp1-2 and Hp2-2, which have 
different biological activity (they are built from a 
and b chains). Haptoglobin has the ability to inhibit 
synthesis of prostaglandins; therefore, it is estima-
ted to have anti-inflammatory and anti-oxidative 
properties [35]. The anti-oxidative property of Hp1-
1 in blood plasma is stronger than that of Hp2-2 as 
its affinity to bind with haemoglobin is stronger 
than that of Hp2-2. Another crucial function of 
haptoglobin is connected with angiogenesis — in 
blood serum Hp may be a promoter of growth of 
endothelial cells of the blood vessels [36]. Hapto-
globin gene polymorphism has been the subject 
of several research projects into different chronic 
diseases, including neoplasms of the respirato-
ry system; however, it has not been studied on 
a large scale with respect to occurrence of chro-
nic obstructive pulmonary disease. Research 
carried out in 1996 showed a rare occurrence of 
the 2/2 homozygote in patients with diagnosed 
adenocarcinoma of the lung [33], and a study 
carried out in 2002 seemed to confirm this [37]. 
Recent research into new markers for the detec-
tion of lung cancer has proven an increase in 
haptoglobin levels in blood serum in patients 
with diagnosed lung cancer [38]. Furthermore, 
it has been shown that in this case haptoglobin 
with a b chain has a greater diagnostic value; the 
concentration of this form of protein is four times 
greater in patients with lung adenocarcinoma in 
comparison with healthy humans.
Proteolytic enzyme genes and inhibitor genes 
of these enzymes were analysed lastly. In the case 
of the MMP1 (1607 1G/2G), MMP9 (C-1562T) and 
MMP12 (Asn357Ser) gene polymorphisms, no 
statistically significant differences were noted in 
either group of patients. The results of analysis of 
MMP3 (6A/5) gene polymorphism appears to be sta-
tistically significant; in the case of MMP12 (A-82G) 
gene polymorphism, the differences between the 
genotypes showed a tendency toward significance. 
The results of hitherto conducted research projects 
into the role of MMP in neoplastic diseases sug-
gests a higher probability of tumour invasion and 
metastasis formation in cases of overexpression of 
MMP1 [16, 39]. MMP-9 has been associated with 
pathogenesis of the development of pulmonary 
emphysema; this enzyme is also important in the 
progression of neoplastic changes in the course 
of lung cancer, especially the disturbed relation 
of MMP-9 to its natural inhibitor TIMP-1 [40]. 
Research conducted by Su et al. showed, in the 
evaluated MMP1(1607 1G/2G) polymorphism, an 
increased risk of lung cancer occurrence in patients 
with the 2G/2G homozygote and a lack of such 
dependence in patients with the 1G/1G and 1G/2G 
genotypes [39]. Subsequent studies have confirmed 
an increased risk of lung cancer occurrence in 
patients with the 2G/2G homozygote [41]. In the 
MMP gene group, a statistical significance was 
obtained only in the case of MMP3 polymorphism 
(6A/5A). The occurrence of the 6A/6A homozygote 
was revealed twice as often in the group of patients 
with cancer +COPD, and the occurrence of the 
5A/5A homozygote was shown almost twice as 
often. The 6A/5A heterozygote was noted nearly 
twice as often in patients with COPD only. MMP3 
may influence the process of carcinogenesis and 
the growth of neoplastic tumours [42]. It has been 
suggested that the 5A/6A genotype favours a higher 
risk of occurrence of certain neoplasms, including 
adenocarcinoma of the breast. However, there 
are only a few reports on lung cancer — research 
among the Chinese population has suggested an 
increased risk of the occurrence of non-small cell 
lung cancer in tobacco smokers with the 5A/5A 
homozygote [43]. Another study by Chinese rese-
archers in 2005 showed a probable coexistence of 
a combination of genotypes of the MMP1, MMP3 
and MMP12 genes, which give an increased risk 
of lung cancer occurrence [18]. In the case of 
MMP12, two polymorphisms of were evaluated, 
i.e. Asn357Ser and A-82G. No statistically signi-
ficant differences were found between the groups 
in relation to the first polymorphism. The A/A 
homozygote occurred more frequently in patients 
only with COPD; the A/G heterozygote occurred 
more frequently in patients with lung cancer and 
COPD (statistical tendency). In the available lite-
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rature the role of MMP12 gene polymorphism in 
the risk of development of lung neoplasms has not 
yet been defined. Polymorphism of the inhibitor 
gene of metalloproteinases TIMP2 G/C has shown 
the occurrence only of the G/G genotype in all the 
studied patients.
The small number of patients who participated 
in the research makes it difficult to draw definite 
conclusions. Therefore, it may be presumed that 
extension of the groups would make the obtained 
results more objective. Furthermore, continued 
observation of the patients with COPD only with 
regard to the possible occurrence of lung cancer 
could increase the reliability of the evaluation of 
polymorphic variants.
Conclusions
A comparative analysis of patients with lung 
cancer and COPD and patients with COPD only, 
showed statistically significant differences in 
the polymorphism of genes connected with iron 
metabolism. The gene of haptoglobin Hp 1/2 was 
connected with iron metabolism and showed diffe-
rences in polymorphism. Patients with lung cancer 
and COPD only significantly more rarely had the 
1/1 homozygote, and they had the 1/2 heterozygote 
more frequently than patients with COPD only. 
The above results might suggest some protective 
significance of the 1/1 homozygote in the case of 
evaluation of lung cancer risk; this may be con-
nected with the greater antioxidative ability of this 
haptoglobin form in plasma.
In the scope of polymorphism of genes con-
nected with proteolytic enzymes, statistically 
significant differences were noted concerning the 
MMP3 gene. The 5A/5A homozygote and the 6A/6A 
homozygote occurred more often in patients with 
lung cancer and COPD. Patients with COPD only 
were more often the 6A/5A heterozygote, which 
could suggest some protective significance of this 
genotype in relation to the risk of occurrence of 
non-small cell lung cancer. The A/G heterozygote 
and the G/G homozygotes of the MMP12 gene 
(A-82) occurred more frequently in patients with 
lung cancer and COPD, whereas the A/A homo-
zygote was seen more frequently in patients with 
COPD only. These differences were non-significant; 
it is possible that further research conducted on 
a larger group of patients would allow verification 
of these data.
Differences in polymorphism of DNA repair ge-
nes and the genes connected with neoplasms proved 
to be insignificant to the risk of lung cancer occur-
rence in patients with COPD in the presented study.
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